Novigenix SA, a leader in immunotranscriptomic diagnostics, today announced the formal spin-out and launch of Novigenix AI, a new precision medicine company dedicated to transforming therapy development through AI-powered immune intelligence.
A Strategic Separation to Unlock Two High-Growth Markets
The new AI spin-out separates Novigenix’s colorectal cancer (CRC) screening business from its rapidly growing AI-driven biopharma and precision medicine platform, allowing each entity to pursue focused go-to-market strategies, tailored capital structures, and distinct partnership pathways.
